Mr. Sofer specializes in medical device development, regulation, reimbursement and marketing, and has more than 20 years of experience in business across different industries including homeland security, manufacturing and trading. He has held executive positions in a number of public and private enterprises, and has broad experience with the capital markets as well as mergers and acquisitions. From 2003 – 2015 he was co-founder, CEO and Board member at Brainsway, an Israeli medical device company, and previously served as CFO at Hofit Company. Mr. Sofer holds a B.Sc. in Accounting and Finance from the Jerusalem College of Technology.
Morry Blumenfeld, PhD
Morry Blumenfeld is President and CEO of Quescon Consultants, Ltd, a medical device consulting company as well as Founding Partner of Meditech Advisors Management. Having been with General Electric for over 34 years, Morry spent the last 27 years of his career with GE Healthcare, the last 4 of which were spent as Managing Director of GE Medical Systems in Israel. Dr. Blumenfeld earned his B.A.Sc. in Engineering Physics and Ph.D. in Molecular Physics from the University of Toronto.
Alan Adler was Chairman of the Board and CEO of Israeli-based Oridion Ltd, a global leader in patient monitoring systems, from 2004 until the company was acquired by a major American healthcare conglomerate, Covidien (now Medtronic), in 2012. Prior to that, he had over 14 years of experience as a consultant and partner at McKinsey & Company and, afterwards, as a senior partner at Evergreen, the Israeli venture capital group. He currently serves as a director on the Boards of a number of technology and life science companies. Alan holds a B.Sc. in Mathematics from Rensselaer Polytechnic Institute and an MBA with honors from Stanford University.
Ms. Alon is currently the founder and CEO of Medstrada. From 1997 and until December 24, 2016, Ms. Alon served as a general partner in Pitango Venture Capital. Prior to her tenure at Pitango, Ms. Alon held senior positions with Montgomery Securities from 1981 to 1987, Genesis Securities, LLC from 1993 to 1996, and Kidder Peabody & Co. from 1987 to 1993, and managed her own independent consulting business in San Francisco in the medical devices industry from 1995 to 1996. Ms. Alon was the founder and Chairperson of Israel Life Science Industry, a not-for-profit organization representing the mutual goals of the then approximately 1,000 Israeli life science companies. She has served or serves as chairperson of multiple private and public companies.
Mr. Avruch is a seasoned businessman and serves as CEO, CFO and Board Member on several International companies. His expertise includes finance and restructuring, typically taking projects from early stages to maturity with several large exits on his record. He has experience in the Real Estate, Services and Trade sectors in multiple countries in Europe and the USA. Mr. Avruch studied Accounting and holds a Master’s in Business Administration.
Meir Jakobsohn founded Medison Ltd. in 1996 and spearheaded its growth as a leading international marketing group. He is the third generation of his family to help shape the local healthcare industry. Previously, Meir served as the Chief Operating Officer of M. Jakobsohn Ltd., led by Arye Jakobsohn. M. Jakobsohn Ltd. was a pioneer in opening the local market to global pharmaceutical concerns like Ciba-Geigy (Novartis), which it represented between 1937 and 1995. Mr. Jakobsohn holds a BA in Economics from Bar-Ilan University and an Executive MBA from Bradford University in the UK.
Peter Melnyk has over 25 years of pharmaceutical and medical device industry experience and is currently the CEO of Fortovia Therapeutics, a commercial stage, pharmaceutical company focused on oncology supportive care products. Recently, Peter was Chief Commercial Officer at Novocure, a cancer medical device company, where he built a global commercial platform and infrastructure to launch a new modality of anticancer technology. He also developed business units in various aspects of commercialization including market access and reimbursement in the US, Europe, and Japan. Peter holds a B.Sc. and M.Sc. from McGill University in Montreal, Canada with a concentration on reproductive endocrinology.
Dr. David M. Milch
Former HCCC’s Chairman of the Board of Directors, has been a self-employed independent investor in the life sciences and technology areas for the past 30 years. Recently, Dr. Milch pursued a number of media opportunities, as the lead investor, including Mila-Media, BeTerrific! and others. In 2014, Dr. Milch invested in the first biopharma spinout from well-known genomics research leader Jackson Laboratories, Cyteir Therapeutics, with co-investors Celgene Corporation, Venrock, Silverlake and others. In 2008, Dr. Milch was part of the small angel group which capitalized Games24X7 in India, currently named RummyCircle. Dr. Milch received his B.S. in Biology at Stanford University and his M.D. from Harvard Medical School.